use is typically under a licensed clinicians supervision for research or compounded medical use
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
In previous studies, orforglipron reduced body weight by 12.4% and improved cardiometabolic risk factors after 72 weeks in adults with obesity without diabetes
MCFA-enriched oils, such as coconut oil and palm kernel oil or MCT, are often added to infant formulas as a source of MCFAs to facilitate fat absorption and the growth of infants, especially in formulas designed for low birth weight or preterm infants (13, 14)